


GP 1616



Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION OF: )  
Robert M. Moriarty )  
Raju A. Penmasta )  
Liang Guo )  
Munagala S. Rao )  
Rajendra G. Mehta )  
SERIAL NO.: 09/008,957 )  
FILED: January 20, 1998 )  
FOR: 1 $\alpha$ -HYDROXYVITAMIN D<sub>5</sub>, ITS )  
SYNTHESIS AND USE IN CANCER )  
PREVENTION AND THERAPY )

Art Unit. 1616

Examiner: Badio, B.

RECEIVED

#4  
JUL 14 1999

DEC 28 1998

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

RESPONSE TO ELECTION\RESTRICTION REQUIREMENT UNDER 35 U.S.C 121

Sir:

Applicants have carefully studied the Examiner's remarks in the Office Action dated November 19, 1998 and have noted the Examiner's requirement that Applicants elect a single group for prosecution on the merits. In response, Applicants hereby provisionally elect (with traverse) to prosecute the Invention I (as embodied in Claims 1-6 and 10-14).

Applicants respectfully submit, however, that the restriction requirement is improper because Inventions I and III comprise a single inventive concept and are not patentably distinct.

Claims 1-6 and 10-14 are directed to the Vitamin D5 compound ("Invention I"). Claim 7 is directed to the process for making



the compound ("Invention II"), and Claims 8 and 9 are drawn to a method for using the compound in cancer prevention and therapy

"Invention III").

Inventions I and III are related as product and process of use. The inventions are not distinct because, contrary to Examiner's assertion, the process for using the product as claimed cannot be practiced with another materially different product.

The method of Claims 8 and 9 (Invention III) cannot be practiced with another materially different compound because of the unique efficacy of the claimed compound in preventing mammary lesion formation and its lower toxicity. As noted in the specification at page 4, lines 3-6, "preliminary studies in mice indicate 1 $\alpha$ -Hydroxyvitamin D<sub>3</sub> is useful in preventing development of carcinogen-induced precancerous lesions at non toxic concentrations." See also Table 2 and discussion thereof on pages 19-20. Furthermore, "1 $\alpha$ -Hydroxyvitamin D<sub>3</sub> is less calcemic than a majority of the analogues of vitamin D<sub>3</sub>" which allows its possible use in prevention of cancer. Page 4, lines 15-17. See also Table I and discussion thereof on pages 16-17.

1 $\alpha$ -Hydroxyvitamin D<sub>3</sub> may also be useful in cancer therapy by inducing the production of TGF- $\beta$ 1, a growth factor compound associated with the inhibition of cancer cell growth. Applicants' studies indicated that the extent of induction of TGF- $\beta$ 1 after treatment with 1 $\alpha$ -Hydroxyvitamin D<sub>3</sub> was similar to that observed with the vitamin D<sub>3</sub> analogue, yet 1 $\alpha$ -Hydroxyvitamin D<sub>3</sub> was considerably less toxic. Page 25, lines 4-14.



In summary, the claimed compound appears to have the unique ability to prevent the development of carcinogen-induced precancerous lesions (useful in cancer prevention) and induce the production of TGF- $\beta$ 1 (useful in cancer therapy) at non toxic concentrations. Because of this unique ability, the method for preventing the development of precancerous lesions set forth in Claim 8 and the method for treating cancer set forth in Claim 9 using 1 $\alpha$ -Hydroxyvitamin D<sub>3</sub> cannot be practiced with another materially different product.

Election of Species


In response to paragraph 6 of the Office Action mailed November 19, 1998, Applicants provisionally elect (with traverse) the species disclosed in Figure 2, R group 13. This is also the species described in Claim 1. Applicants respectfully submit, however, that the election requirement is improper because the species comprising the embodiment of R groups defined by compounds 13a-e are obvious variants.

\*\*\*

In view of the foregoing, Applicants respectfully request that the restriction requirement vis a vis Invention I and III be withdrawn upon reconsideration and that the election of species requirement vis a vis R groups defined by compounds 13a-e be withdrawn upon reconsideration.

The Examiner is invited to telephone applicant's undersigned attorney if any unresolved matters remain.

Respectfully submitted,



*Harold J. Fassnacht*  
Harold J. Fassnacht  
Reg. No. 35,507

BULLWINKEL PARTNERS, LTD.  
19 S. LaSalle Street - Suite 1300  
Chicago, Illinois 60603-1493  
Telephone: 312-201-0777

Dated: *12/17/98*

I hereby certify that this correspondence  
is being deposited with the United States  
Postal Service as first class mail in an  
envelope addressed to: Commissioner Of  
Patents And Trademarks, Patent And Trademark  
Office, Washington, D. C. 20231, on  
*December 17*, 19 *98*

*Harold J. Fassnacht*  
Signature